SUMMARY: Methicillin-resistant Staphylococcus aureus (MRSA) has been a public health concern since it was first identified in the United Kingdom in 1961. In this study, we investigated the prevalence of MRSA in the PLA 309 Hospital located in Beijing, China, and we determined the susceptibility of S. aureus to novel oxazolidinone analogs and 13 conventional antimicrobial agents. It was shown that drug resistant patterns were severe among the clinical isolates, and the average rate of MRSA among the S. aureus strains was 56.3z. All the S. aureus strains tested were completely susceptible to linezolid, but the minimum inhibitory concentration distribution drifted upwards. Among the novel oxazolidinone analogs, sy142 exhibited more potent antimicrobial activity than linezolid against both the standard and clinical S. aureus strains. This observation provides an impetus for the development of potential novel agents based on sy142 in the near future to combat MRSA and linezolid-resistant S. aureus.
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged rapidly since it was first identified in the United Kingdom in 1961 and has currently become a challenging problem worldwide (1) . Infections due to MRSA, which usually increases the use of medical resources and the treatment cost, cause considerable morbidity and mortality. According to previous reports, in China, about 35z-80z of S. aureus strains isolated from patients are MRSA (2, 3) . In general, patients who suffer from MRSA infections are treated with glycopeptides such as vancomycin and teicoplanin and the oxazolidinone of linezolid, however, vancomycin-resistant S. aureus (VRSA) has started to emerge, and the duration of treatment with linezolid is limited because of potentially serious neurologic, ophthalmologic, and hematologic toxicities. Therefore, we need an alternative, novel effective antibiotic to cure MRSA. In our previous work, we identified a series of novel 4-substituted piperazinyl phenyl oxazolidinone analogs; however, data on these analogs against MRSA are limited. In the present study, we aimed to summarize the in vitro efficacy of these compounds against MRSA strains isolated from the PLA 309 Hospital located in Beijing, China, which is the treatment center for tuberculosis and respiratory tract infections in the Chinese army.
The bacterial strains used in this study were obtained from the Chinese PLA 309 Hospital from January 2010 to December 2012. A total of 623 S. aureus strains isolated from various clinical specimens of patients were included in this study. All the isolates were independent isolates, and duplicate isolates from the same patient were excluded. The isolates were identified using the MicroScan Walk Away 96 System, and antimicrobial susceptibilities were determined by the broth liquid microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (4). Minimum inhibitory concentration (MIC) was defined as the lowest antimicrobial concentration that completely inhibited bacterial growth. Linezolid was obtained from PROMEGA (Part Number: PZ0014). The novel oxazolidinone analogs were synthesized as described previously (5) at the School of Pharmaceutical Engineering, Shenyang Pharmaceutical University. The structures of the novel oxazolidinone analogs are shown in Fig. 1 . The conventional antimicrobial agents used in this study were penicillin, gentamycin, rifampicin, ciprofloxacin, levofloxacin, moxifloxacin, trimethoprim-sulfamethoxazole, clindamycin, erythromycin, linezolid, vancomycin, quinupristin-dalfopristin, and tetracycline. Methicillin-resistant strains were identified using a 1 mg oxacillin disc on Mueller-Hinton agar according to CLSI guidelines (6) . S. aureus ATCC 29213 was used as the control.
The antimicrobial susceptibilities of S. aureus determined according to CLSI guidelines (4) are summarized in Table 1 . Of 623 isolates studied, 351 (56.3z) were confirmed to be MRSA strains. Penicillin had the lowest activity, followed by erythromycin, levofloxacin, tetracycline, clindamycin, and ciprofloxacin, all of which showed resistance rates that were higher than 60z. Trimethoprim-sulfamethoxazole and quinupristin-dalfopristin exhibited high activity. It must be noted that the activity of erythromycin, rifampicin, and gentamycin significantly decreased in the last 3 years. Although no strains were identified to be resistant to linezolid Antimicrobial Activities of Novel Oxazolidinones (for staphylococci, MIC of AE 8 mg/ml was defined as nonsusceptibility), a significant upwards drift of MIC was observed for this antibiotic in the present study. When compared with previous reports, a larger number of isolates could not be completely inhibited in this study until the linezolid concentration reached 4 mg/ml (2). The novel oxazolidinone compounds were found to exhibit excellent activity against the standard S. aureus strain ATCC 29213, with MIC values ranging from 0.5 to 8 mg/ml (Table 2) . In particular, sy142 demonstrated better antimicrobial activity than linezolid (sy142 MIC ＝ 0.5 mg/ml vs linezolid MIC ＝ 1 mg/ml), and it inhibited all the clinical isolates, with MIC values higher than 1 mg/ml, including the isolates with linezolid MIC that drifted upwards.
Oxazolidinones kill bacteria by blocking the formation of the initiation complex on the ribosome to inhibit bacterial protein synthesis at a site. Linezolid was the first oxazolidinone antibacterial agent approved for clinical use. As this antibiotic acts on a distinctive target, namely 23S ribosomal RNA, many reports have focused on its effect on drug-resistant strains, including MRSA (7, 8) . Although uncommon, investigators have reported the existence of linezolid-resistant S. aureus (LRSA) in some countries. For example, LRSA was detected in the USA soon after linezolid was available in the market in 2001 (9, 10) . To the best of our knowledge, linezolid has been used in many hospitals in China to treat ICU patients infected with MRSA, because this drug was approved in 2007 by the Chinese government. This might be one of the reasons for the upwards drift of linezolid MICs and for the possibility that LRSA might emerge in China in the near future.
In the recent years, many efforts have been taken to develop second-generation oxazolidinones. The currently developed oxazolidinones such as tedizolid (TR-701), LCB01-0062, DA-7218, and DA-7157 have been reported to be more potent and/or exhibit lower toxicity than linezolid (11) (12) (13) . On comparing the difference in the structure and activity between sy142 and linezolid, it could be concluded that the N-heteroaryl group at the 4-position of piperazine is favorable for enhancing the activity of sy142. This observation provides an impetus for designing a novel series of drugs based on sy142 in the near future. Furthermore, considering that sy142 activity was not influenced by the upwards drift of linezolid MIC, novel drugs based on sy142 might possibly be employed to combat MRSA and LRSA.
